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Abstract 
 
Background. Rubia cordifolia has been used to treat various diseases and exhibits antimicrobial, anti-inflammatory, 
analgesic and antidiarrheal activities. The plant has not been investigated for its anti-mycobacterial activity against 
virulent tuberculosis strains as well as cytotoxic and anti-oxidant activities in mononuclear cells and neutrophils.  
Methods. Ethanolic and dichloromethane leaf extract fractions of Rubia cordifolia (0.2- 125µg/ml) were screened for 
anti-mycobacterial activity using a fluorescent microplate assay. The anti-oxidant activity of the fractions was tested 
using the radical scavenging assay, while their cytotoxicity to lymphocytes was measured using the WST-8 assay. 
Reactive oxygen species production by neutrophils exposed to fractions was tested using Cell Meter™ Fluorimetric 
ROS Assay kit.   
Results. The ethanolic leaf fractions exhibited overall superior anti-mycobacterial activity than the dichloromethane 
group and were further screened for anti-oxidant and cytotoxic activities. Ethanolic sub-fractions K2F-3.2, K2F-3.3 and 
K2F-3.4 showed significant antioxidant activities at concentration of 50 µg/ml to 200 µg/ml and higher in both the cell 
free-based radical scavenging activity and total reactive oxygen species production assays. For lymphocytes, the test 
agents showed anti-proliferative activity at 25 µg/ml to 200 µg/ml for sub-fraction K2F-3.3B and 50 µg/ml to 200 
µg/ml for agents K2F-3.2 and K2F-3.4. 
Conclusion. The current study is the first to record the in vitro anti-mycobacterial, anti-oxidant and cytotoxic activities 
of Rubia cordifolia plant leaf extract sub-fractions using the given experimental setups and further research activities to 
identify the bioactive components are to be pursued.  
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Introduction 
 
Tuberculosis (TB), compared to HIV/AIDS, is the second highest communicable disease that leads to high 
mortality rates worldwide due to Mycobacterium tuberculosis (WHO, 2014; WHO, 2015). The disease is expected to 
surge in the future due to various forms of multidrug drug resistance (MDR): multidrug resistant (MDR), extremely 
drug resistant and (XDR) and totally drug resistant (TDR) tuberculosis and co-infection with human immunodeficiency 
virus (HIV) (Mistry et al., 2012; Abubakar et al., 2013 and WHO, 2015). The South African TB/HIV/AIDS co-
infections are extremely high with 73% of TB patients co-infected with HIV (Soul City Research Unit, 2015). This 
situation calls for an emergence prioritisation of development of new and novel agents for TB treatment and 
management.  
There is a resurgence of research activities to explore the use of medicinal plant bio-products as potential anti-
mycobacterial agents in South Africa (Lall and Meyer, 1999; Bapela et al., 2006; Eldeen and Van Staden, 2008; Green 
et al., 2010; Labischagné et al., 2012; Aro et al., 2016 and Komape et al., 2017). Plant extracts with high anti-oxidant 
capacity have been presented as exhibiting bactericidal activity against Mycobacterium tuberculosis (Newton et al., 
2000; Okunade et al., 2004; Pauli et al., 2005 and Gouveia-Figueira et al., 2014; Magadula et al., 2012). Tuberculosis 
as an infection present an inflammatory response in the lungs whereby cellular mediators are released causing oxidative 
stress (Sommer, 2005). The most vital of the mediators are reactive oxygen species (ROS) and hydrogen peroxide 
(H2O2). Excess production of these oxidants leads to harmful inflammatory reactions in the lungs (caseous necrosis) 
and antioxidant material that scavenges and eliminate ROS may be important in preventing or minimizing oxidative-
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related damage in clinical conditions like tuberculosis (Constantino et al., 1992; Reljic et al., 2010; Bernardes et al., 
2014 and Dzoyem and Ellof, 2015).  
Other studies have focused on the repurposing of compounds that have anti-inflammatory activity as they 
present an alternative to combating increased antimicrobial drug resistance (Kulkarni and Deshpande, 2016; Maitra et 
al., 2016 and Prasad et al., 2016). Plant products or chemical entities that exhibits antimicrobial and anti-inflammatory 
activities should be considered for prospects in combatting Mycobacterial tuberculosis infection (Trevisan et al., 2016). 
Rubia cordifolia Linn. (Rubiaceae) is also known by other common names like Manjistha and Majith depending on the 
geographical location. It is distributed in tropical Africa, India, Japan and Indonesia (Tailor et al., 2010; Deshkar et al., 
2008). The various parts of the plant have been shown to exhibit a myriad of ethno-medicinal applications like: anti-
diarrheal, anti-inflammatory, antimicrobial, antipyretic and analgesic activities (Kasture et.al 2000; Joharapurkar et.al., 
2003; Devi Priya and Siril., 2014; Verma et.al., 2016; Gong et.al., 2017). Medicinal plants and their bioactive 
compounds can serve as an alternative choice for resistant Tuberculosis treatment, provided the agents are less toxic 
and anti-inflammatory because Tuberculosis is a highly inflammatory phenomenon that damages lungs (Semenya and 
Maroyi, 2013; Nyambuya et al., 2017; Komape et al., 2017).    
To this end, the anti-mycobacterial activity of crude ethanolic and dichloromethane (DCM) leaf extracts of 
Rubia cordifolia were investigated for anti-mycobacterial activity in vitro. The crude extracts that exhibited the most 
potent activity were further fractionated to screen for possible: anti-mycobacterial, antioxidant and anti-proliferative 
activities. 
 
Materials and Methods 
 
Unless otherwise indicated, all chemicals and reagents were obtained from Sigma-Aldrich (Johannesburg, 
South Africa). 
 
Plant collection and preparation of leaf extracts and sub-fractions  
 
Rubia cordifolia plants were collected from traditional healers in Tzaneen (Mopani District, Limpopo 
Province, South Africa) and a voucher specimen of the plant was deposited in the University of Limpopo Herbarium 
under the accession number 11208. Ethanol (100 ml) was added to 5 g of dried powder from plant leafs in a 500 ml 
volumetric flask. The resultant mixture was stirred at room temperature for 24 h. The mixture was filtered to remove 
undissolved material and then washed with 2 x 10 ml Ethanol. The solvent was removed in a rotary evaporator to give 
2.233 g of crude extract. The crude extract was then subjected to preparative thin layer chromatography (prep-TLC), 
eluting with methanol-DCM (1:19) to give four fractions.   
 
Green fluorescent protein microplate assay (GFPMA) for anti-mycobacterial screening 
 
This broth micro dilution technique (Collins et. al., 1998) allows an array of drug concentrations to be 
screened on a single 96-well microtitre plate in order to determine minimum inhibitory concentration (MIC). Briefly, 
culture (10 ml) of a mutant Mycobacterium tuberculosis (H37RVMA) strain (Ioerger et.al., 2010) constitutively 
expressing recombinant green fluorescent protein (GFP) is grown to an OD600 of 0.6-0.7 and diluted 1:100 in GAST/Fe 
medium. To the wells of the test plate was added 100 µl of culture suspension and two-fold dilutions of the test agents 
(0.2-125 µg/ml, final concentration) in triplicates to a final volume of 200 µl. Control wells contained untreated 
bacterial culture suspensions (positive control) and medium only (background control). The plates were incubated at 
37oC and fluorescence measured at day 7 post incubation using a Flurostar Optima microplate reader (BMG Labtech, 
Thermofisher Scientific, USA) with excitation at 484 nm and emission at 508 nm. Percent inhibition was calculated as 
1- (test well FU/FU of background wells X 100). MIC was expressed as the lowest drug concentration inhibiting 90% 
and 99% of bacterial growth.    
 
Determination of antioxidant activity of ethanolic sub-fractions by DPPH method 
 
The radical scavenging activity of the extract was determined by the method described by Krings and Berger 
(Krings and Berger, 2001). To 1 ml of 0.1 mM solution of DPPH in ethanol, was added 3 ml of test agents (6-
200μg/ml) in distilled water and kept for 30 minutes. The colour change of the reaction mixture was then read at 517 
nm in a plate reader DXT 800 multimode plate reader (Beckman Coulter, Johannesburg, South Africa). 
 
Preparation of PBMCs from human peripheral blood 
 
PBMCs were obtained by collecting venous blood (8ml) into specialised BD Vacutainer® CPT™ tubes 
according to the manufacturer’s instruction (Beckton Dickinson, Johannesburg, South Africa). Ethical approval to draw 
blood from donors was obtained from the University of Limpopo Research and Ethics Committee 
(TREC/117/2016:UG). 
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Isolation of neutrophils from human peripheral blood 
 
Purified neutrophils were prepared from heparinized venous blood of healthy adult human volunteers and 
were separated from mononuclear leukocytes by centrifugation on Histopague-1077 at 300 g for 25 min at 40C. After 
removal of the plasma and mononuclear cell layers, 5ml of Verasylase was added to the residual red blood cell pellet 
that contained neutrophils and incubated for 15 min to lyse the erythrocytes. After incubation, the suspension was 
resuspended in abundant HBSS buffer and centrifuged at 160 g for 10 min. The supernatant was aspirated and the pellet 
washed twice in HBSS at 110 g for 10 min. Neutrophils of high purity (>90%) were prepared at 2 x 107cells/ml and 
held on ice before assaying for total ROS production.    
 
Detection of total ROS production by ethanolic sub-fractions on purified neutrophils 
 
Cells were incubated for 5 min with or without test material (6-200 µg/ml) and ROS production detected using 
a Cell Meter™ Fluorimetric ROS Assay Kit according to the manufacturer’s instruction (Cayman Chemical, 
Johannesburg, South Africa).  
 
Determination of growth inhibitory effects of ethanolic sub-fractions on human lymphocytes  
 
After incubating the PBMCs (2 x 106 cells/ml) for 72 hours with or without plant isolates (6-200 µg/ml), 
proliferative activity was determined using the WST-8 assay following the manufacturer’s instructions (Cayman 
Chemicals, Johannesburg, South Africa). 
 
Data analysis 
 
Numerical data of experiments (repeats of 3-4 experiments in triplicates) was analysed using Microsoft Excel 
2009 Version for Windows. Results are expressed as mean ± SD (Standard deviation). A p≤0.05 considered to be 
significant.  
 
Results 
 
Anti-mycobacterial activity of Rubia cordifolia leaves were tested on DCM and ethanolic extracts against 
H37Rv strain of Mycobacterium tuberculosis using the green fluorescence protein microplate assay (GFPMA). The 
ethanolic crude extract (K2F-3) was less active than the DCM (K2F-1) crude extract, with MIC90 of 57.3 and 44.5 
µg/ml respectively as shown in Table 1 and Table 2 respectively. Fractionation of the crude extracts by preparative 
chromatography, eluting with 5% methanol-DCM afforded four sub-fractions from each crude. The sub-fractions from 
the ethanol crude demonstrated better activity compared to those obtained from the DCM crude (Table 1 and 2) and 
were further screened for anti-oxidant activity.  
 
Table 1: Minimum inhibitory concentrations (MIC90 and MIC99) of ethanolic leaf extracts of Rubia cordifolia against 
the H37Rv strain of Mycobacterium tuberculosis. 
Sample name MIC
90
 (μg/ml) MIC
99 
(μg/ml)
          
 
K2F-3 (Ethanol crude) 57.3 63.7 
K2F-3.1 35.5 41.2 
K2F-3.2 26.2 28.7 
K2F-3.3 38.8 45.8 
K2F-3.4 39.4 41 
 
Table 2: Minimum inhibitory concentrations (MIC90 and MIC99) of DCM leaf extracts of Rubia cordifolia against the 
H37Rv strain of Mycobacterium tuberculosis.   
Sample name MIC
90
 (μg/ml) MIC
99 
(μg/ml)
          
 
K2F-1 (DCM crude) 44.5 57 
K2F-1.1 52.8 57.8 
K2F-1.2 71.6 82.7 
K2F-1.3 40.2 46.9 
K2F-1.4 27.5 30.2 
 
The DPPH radical scavenging activity measures the antioxidant potential of the ethanolic sub-fractions of 
Rubia cordifolia as shown in Figure 1. The results show that sub-fractions K2F-3.2 B, KF-3.3B and K2F-3.4B exhibits 
significant DPPH activity (more than 60%) from 50 µg/ml to 200 µg/ml (p < 0.05) with sub-fraction K2F-3.1B 
showing no activity at the concentrations tested (p > 0.05). A p < 0.05 value also indicates a comparable and significant 
DPPH activity by the ethanolic crude extract as is Vitamin B12 which acted as the positive control in this instance. The 
three sub-fractions exhibiting significant DPPH activity were then further screened for total ROS production and 
cytotoxic activity in isolated neutrophils and lymphocytes.  
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Figure 1: The free radical scavenging activity of ethanolic leaf extract sub-fractions of Rubia cordifolia as determined 
by the DPPH assay. Results are expressed as mean percentage DPPH activity by the test agents (6-200 µg/ml) plus 
SEM of four different experiments conducted in triplicates. *The result is statistically significant. 
 
Results for the production of total reactive oxygen species (ROS) by human neutrophils using the Cell 
Meter™ Fluorimetric ROS Assay Kit are shown in Figure 2. There is an indication of a dose-dependent increase in 
total ROS production by the three sub-fractions, with sub-fraction K2F-3.3B exhibiting significant activity from 25 
µg/ml to 200 µg/ml (p < 0.05) while sub-fractions are active from 50 µg/ml to 200 µg/ml (p < 0.05).  
 
 
 
Figure 2: Percentage inhibition of ROS production by ethanolic leaf extract sub-fractions of Rubia cordifolia in 
neutrophils in vitro. Results are expressed as the mean percentage of inhibition of ROS production by the test agents (6-
200 µg/ml) plus SEM of four different experiments conducted in triplicates. *The result is statistically significant. 
 
The cytotoxic activity of the three ethanolic sub-fractions of R. cordifolia against peripheral blood 
mononuclear cells (lymphocytes) using the WST-8 assay are indicated in Figure 3. Ethanolic fraction K2F-3.3B did 
show a significant inhibition of lymphocyte proliferation from 25 µg/ml and higher (p < 0.05) while the other two 
agents, K2F-3.2B and K2F-3.4 exhibited observable cytotoxic activity from 50 µg/ml and higher (p < 0.05) as shown in 
the figure. 
 
 
*** 
*** 
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Figure 3: Percentage cell proliferation inhibition by ethanolic leaf extract sub-fractions of Rubia cordifolia on 
lymphocytes in vitro. Results are expressed as the mean percentage inhibition of cell proliferation by test agents (6-200 
µg/ml) plus SEM of four different experiments conducted in triplicates. *The result is statistically significant. 
 
Discussion and Conclusion 
 
The current study present results of ethanolic leaf extract sub-fractions of Rubia cordifolia showing superior 
antimycobacterial activity to that of the DCM sub-fractions at IC90 values of less than 50 µg/ml compared to that of the 
DCM test material (highest IC90 value of 72 µg/ml). The concentration range attained for in vitro anti-mycobacterial 
activity in this study is comparable or lower to other studies recently reported for different plant and mycobacterial 
species as well as experimental procedures employed (Bernadres et.al., 2016; Nguta et.al., 2016; Trevisan et.al, 2016; 
Komape etal., 2017; Nyambuya et.al., 2017).  
The other part of the investigations focused on screening the antioxidant and anti-proliferative activities of the 
ethanolic leaf extracts sub-fractions. Pro-inflammatory mediators play a significant part in protective immunity in 
tuberculosis and their maintenance and strict control is important to avoid immunopathic cases due to excessive and 
inappropriate production (Lyadova and Panteleev, 2015; Amaral et.al., 2016; Piñeros et.al., 2017). Only three of the 
sub-fractions: KF2-3.2B, K2F-3.3B and K2F-3.4 exhibited dose-dependent antioxidant and anti-proliferative activities 
that attained prominence from 50 µg/ml to 200 µg/ml. There is apparently paucity of literature reports on the screening 
of leafs extracts of Rubia cordifolia in laboratory experimental models used in the current study. 
Various studies conducted to investigate the anti-inflammatory and antioxidant potential of Rubia cordifolia 
used roots and stems as screening material (Patil et.al., 2006; Basu and Hazra, 2006; Karodi et.al., 2009; Deoda et al., 
2011). The laboratory experimental systems used for anti-inflammatory activity are ex vixo and mostly animal models 
(Lopez-Exposito et.al., 2011; Gong et.al, 2017). The present study affirms that leaf extract sub-fractions of Rubia 
cordifolia does exhibit cytotoxic and antioxidant activities at acceptable concentrations even when different laboratory 
experimental models are used. In this case we used isolated human peripheral blood mononuclear cells (lymphocytes) 
and neutrophils. The anti-proliferative and antioxidant properties of leafs of Rubia cordifolia are consistent with them 
containing various chemical derivatives of anthraquinones (Devi Priya and Siril, 2014; Sreenu et.al., 2014; Maharjan 
and Nampoothiri, 2015; Panigrahi et.al., 2016; Verma et.al., 2016).  
The anti-mycobacterial, cytotoxic and antioxidant activities of three ethanolic leaf extract sub-fractions of 
Rubia cordifolia are still preliminary and further laboratory work is warranted to: isolate their bioactive elements, 
elucidate their apoptotic pathways and screen various drug combination schema in in vitro and animal models of 
experimental Tuberculosis. 
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